Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi AppTec and Schrödinger Form Faxian for Novel Drug Discovery

publication date: Oct 30, 2018

WuXi AppTec will form Faxian Therapeutics with Schrödinger, a New York City company that offers drug discovery using advanced computational methods. WuXi will add its lead optimization CRO services to advance molecules discovered by Schrödinger's precision molecular design platforms. Faxian, which will presumably own and develop the candidates, will concentrate on novel insights into the chemistry and biology of a target and indication. More details....

Stock Symbol: (SHA: 603259)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.